LATAM Fabry Disease Market, by Therapy Type (Enzyme Replacement Therapy (Agalsidase Beta (Fabrazyme), Agalsidase Alfa (Replagal), Pegunigalsidase Alfa (PRX-102, Phase III)) Chaperon Therapy (Migalastat (Galafold Phase III)), Substrate Reduction Therapy (Lucerastat (Phase III), Venglustat (Phase III))), by Route of Administration (Oral, Parenteral), by Distribution Channel (Hospitals Pharmacies, Online pharmacies, Retail Pharmacies), and by Country (Brazil, Argentina, Mexico, Rest of Latin America) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Sep 2022

Code : CMI5249

Pages :245

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Challenges And Opportunities

LATAM Fabry Disease Market – Restraints

Lack of proper treatment for fabry disease in countries of Latin America is expected to hamper growth of the LATAM fabry disease market, over the forecast period. For instance, according to an article published on February 10, 2021, by National Center for Biotechnology Information, Brazil is at the risk for the availability of the treatments such as enzyme replacement therapy, for the patiens with Fabry disease. Brazil is one of the populated country in Latin America and lack of proper treatment for the patients with fabry disease is expected to hamper growth of the LATAM fabry disease market.

LATAM Fabry Disease Market – Country Analysis

On the basis of Country, the LATAM fabry disease market is segmented into Brazil, Mexico, Argentina and Rest of Latin America.

Among Country, Argentina fabry disease market is expected to hold a dominant position during the forecast period, owing to increasing prevalence of patients with fabry disease. For instance, according to an article published on March, 2018, by National Center for Biotechnology Information, A team of researcher estimated the prevalence of fabry disease in Argentina of young adults who had stroke and reported that 3% of patients were identified with fabry disease.

Furthermore, Brazil is also estimated to witness significant growth in the LATAM fabry disease market, owing to increasing research and development by research institutes in collaboration with key market players. For instance, according to the source clinicaltrials.gov University of Sao Paulo General Hospital in collaboration with Pfizer Inc., a pharmaceutical company, on September 9, 2020 had started clinical trials for Noninvasive Assessment of Myocardial Stiffness by 2D-SWE Ultrasound Technique (Two-dimensional Shear Wave Elastography) in Patients With Amyloidosis and Fabry Disease to evaluate the diastolic myocardial elasticity in patients with Fabry disease and compare it with the transthyretin amyloidosis group with cardiac involvement.

Figure 2: LATAM Fabry Disease Market (US$ Bn), by Country, 2022